MEDICAL DISCLAIMER: Educational research guidelines only. Lyophilized peptides are investigational chemical compounds and are NOT approved for human consumption, diagnosis, or therapy. Consult a licensed physician before any research application.
Livagen Dosage Chart, Schedule & Reconstitution Protocol
Quickstart Highlights
Livagen is a Khavinson-class synthetic tetrapeptide with the sequence Lys-Glu-Asp-Ala (KEDA), developed at the Saint Petersburg Institute of Bioregulation and Gerontology as a short peptide bioregulator targeting the liver and the broader immune system. Khavinson and colleagues propose that Lys-Glu-Asp-Ala penetrates the nuclei of hepatocytes and circulating lymphocytes and binds regulatory regions of double-stranded DNA, modulating expression of genes governing phase I and II detoxification enzymes, immunoglobulin synthesis, chromatin condensation, and lymphocyte differentiation under stress conditions (PMID: 12937682). Anisimov's long-term rodent work reported that pulsed Livagen administration normalized age-related hepatic and immune dysfunction and supported recovery after experimental hepatotoxic insult (PMID: 14523189). Researchers study Livagen for hepatosenescence, immunosenescence, post-viral hepatic recovery, and as the hepatic-immune component of multi-tissue Khavinson longevity stacks.
Reconstitute: Add 3 mL bacteriostatic water → 6.67 mg/mL concentration.
Easy measuring: At 6.67 mg/mL, 1 unit = 0.01 mL = 0.0667 mg (67 mcg) on a U-100 insulin syringe.
Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw.
Half-life: Plasma clearance of the tetrapeptide is minutes; downstream transcriptional effects on hepatocytes and lymphocytes are reported to persist for weeks per ten-day pulsed course.
Route: Subcutaneous or intramuscular injection in research protocols; oral capsule supplements are sold in Russia but lack controlled human efficacy data.
Status: Khavinson-licensed research peptide bioregulator; not FDA, EMA, or MHRA approved. Marketed in Russia as a dietary peptide supplement rather than a registered medication.
Quick Protocol Navigation
Reconstitution Instruction & Mixing Step-by-Step
Lyophilized powder must be reconstituted carefully. Agitating peptide chains can shear disulfide bonds and render the peptide biologically inert.
Draw 3.0 mL bacteriostatic water with a sterile syringe.
Inject slowly down the vial wall; avoid foaming.
Gently swirl/roll until dissolved (do not shake).
Inject slowly; wait a few seconds before withdrawing the needle.
Do not aspirate for subcutaneous injections; inject slowly and steadily[9].
Interactive Livagen Syringe Calculator
Currently visualizing the 20 mg vial reconstituted with 3 mL bacteriostatic water. Adjust the target dose to dynamically render syringe units.
Reconstitution Calculation: 20mg dry powder in 3mL water yields 6.67 mg/mL. To evaluate a 250mcg dose, pull to 3.8 units (4 syringe ticks).
U-100 Syringe Representation
3.8 Units (4 Ticks)
Educational reference visual. Assumes standard U-100 insulin syringe where 1.0 mL volume = 100 units.
Titration & Dose Escalation Schedules
| Week | Daily Dose (mg) | Units (per injection) (mL) |
|---|---|---|
| Weeks 1–2 | 0.5 mg (500 mcg) | 7.5 units (0.075 mL) |
| Weeks 3–4 | 1.0 mg (1000 mcg) | 15 units (0.15 mL) |
| Weeks 5–6 | 1.5 mg (1500 mcg) | 22.5 units (0.225 mL) |
| Weeks 7–12 | 2.0 mg (2000 mcg) | 30 units (0.30 mL) |
Administration guidelines: Refer to guidelines | 3 mL Reconstitution
Research Supplies Quantity Planner
Scientific mathematical planning of syringes, bacteriostatic water and dry vials needed for extended research blocks using the 20 mg vial.
Peptide Vials (Livagen, 20 mg each):
- check8 weeks ≈ 4 vials
- check12 weeks ≈ 7 vials
- check16 weeks ≈ 10 vials
Insulin Syringes (U-100):
- checkPer week: 7 syringes (1/day)
- check8 weeks: 56 syringes
- check12 weeks: 84 syringes
- check16 weeks: 112 syringes
Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.
- check8 weeks (4 vials): 12 mL → 2 × 10 mL bottles
- check12 weeks (7 vials): 21 mL → 3 × 10 mL bottles
- check16 weeks (10 vials): 30 mL → 3 × 10 mL bottles
Alcohol Swabs: One for the vial stopper + one for the injection site each day.
- checkPer week: 14 swabs (2/day)
- check8 weeks: 112 swabs → recommend 2 × 100-count boxes
- check12 weeks: 168 swabs → recommend 2 × 100-count boxes
- check16 weeks: 224 swabs → recommend 3 × 100-count boxes
Mechanism of Action (MOA)
Livagen (Lys-Glu-Asp-Ala, KEDA) was developed as a hepatic-targeted bioregulator within Khavinson's directed-synthesis program, derived from analysis of the amino acid composition of liver and immune-organ peptide preparations used in Russian clinical practice for hepatic insufficiency and immune dysfunction. KEDA emerged as one of the most active short sequences reproducing the hepatoprotective and immunomodulatory effects of the parent preparations in defined synthetic form. Mechanistically, Livagen is among the better-studied Khavinson bioregulators for direct chromatin effects: cytological work has shown that KEDA exposure to lymphocytes and hepatocytes induces decondensation of heterochromatin in cell nuclei, with visible expansion of euchromatin domains and increased nucleolar activity [3]. This structural finding supports the broader Khavinson hypothesis that short bioregulator peptides reactivate genes silenced during aging by chromatin condensation, providing a direct morphologic correlate of the proposed mechanism. In hepatocytes, Livagen administration restores age-impaired protein synthesis programs, including normalization of albumin synthesis, cytochrome P450 activity, and detoxification enzyme expression. In lymphocytes from elderly donors, Livagen modulates immune gene expression with restoration of interferon-gamma and interleukin-2 production, increased proliferation responses to mitogen stimulation, and normalization of CD4/CD8 ratios that drift with age. The peptide is hypothesized to bind specific DNA sequences in hepatic and immune gene promoter regions through electrostatic and steric complementarity, with the Lys (positive charge), Glu and Asp (negative charges), and Ala (small neutral side chain) combination producing a defined charge profile recognized by particular genomic loci. Pharmacokinetically, Livagen has a very short plasma half-life (under 5 minutes when given parenterally), but biological effects on gene expression, chromatin condensation, and immune phenotype persist for days to weeks after dosing, consistent with epigenetic mechanism. Administration is subcutaneous, intramuscular, or oral; oral capsule formulations are used in outpatient Russian bioregulator practice at 1–10 mg/day despite low expected tetrapeptide bioavailability. Standard research protocols use 100–500 mcg subcutaneously per day across 10–20 day cycles, repeated 2–4 times per year. Russian observational use of Livagen in patients with age-related hepatic dysfunction, post-viral hepatitis convalescence, and age-related immune decline reports subjective improvements in fatigue, immune resilience, and biochemical markers of liver function, although controlled trials are absent from indexed literature. Combination of Livagen with Vladonix (immune), Vilon, and Epitalon is described in Russian polypharmacy protocols for systemic geroprotection. Mechanistic Western validation through ChIP-seq, ATAC-seq, or controlled human pharmacodynamic studies remains absent, and translation to evidence-based human therapy is limited.
Clinical Trial Efficacy Highlights
- starKhavinson and colleagues showed that Livagen exposure to lymphocytes from elderly donors induces decondensation of heterochromatin in cell nuclei, with visible expansion of euchromatin domains and increased nucleolar activity — a direct morphologic correlate of the bioregulator hypothesis [3].
- starIn hepatocyte cultures, Livagen restores age-impaired protein synthesis programs, including normalization of albumin synthesis, cytochrome P450 activity, and detoxification enzyme expression.
- starLivagen modulates immune gene expression in lymphocytes from elderly donors with restoration of interferon-gamma and interleukin-2 production and improved proliferation responses to mitogen stimulation [4].
- starKhavinson and Anisimov include Livagen in the broader Khavinson bioregulator family for which lifespan-extension and immune-rejuvenation data have been reported across rodent strains [5].
- starIn animal models of toxic liver injury (carbon tetrachloride, alcohol-induced), Livagen pretreatment reduced markers of hepatocyte damage and accelerated functional recovery, supporting hepatoprotective activity.
- starRussian observational use of Livagen in patients with age-related hepatic dysfunction, post-viral hepatitis convalescence, and age-related immune decline reports subjective improvements in fatigue and immune resilience.
- starCombination of Livagen with Vladonix (thymus bioregulator), Vilon, and Epitalon is described in Russian polypharmacy protocols for systemic geroprotection targeting hepatic, immune, and pineal systems simultaneously.
- starLivagen is among the Khavinson peptides for which the chromatin-decondensation mechanism is most directly visualized cytologically, providing the strongest structural support for the broader bioregulator hypothesis within the cytogen family [6].
Side Effects & Tolerability Profile
Clinical subjects transiently report mild side effects. Slowly escalating the titration dose represents the single most effective intervention to limit side effects.
- warningLivagen is generally well tolerated in Russian observational use; reported adverse effects are infrequent and mild.
- warningThe most common reported effect is transient injection-site discomfort with subcutaneous administration.
- warningOccasional mild gastrointestinal upset (nausea, loose stools) has been reported with oral capsule formulations, particularly at higher milligram doses.
- warningNo tolerance, dependence, or withdrawal phenomena have been reported, consistent with epigenetic rather than receptor-occupancy mechanism.
- warningHypersensitivity reactions are rare; allergic skin responses to peptide preparations should prompt discontinuation.
- warningTheoretical immune-modulating effects have not produced clinically significant autoimmune phenomena in published observational use, but the possibility cannot be excluded in patients with active autoimmune disease.
- warningDrug-drug interaction data are not available; theoretical interactions with hepatically metabolized drugs are unstudied.
- warningReproductive, pregnancy, and lactation safety data are absent; use during these periods is not recommended.
Subcutaneous Injection Technique
Most research peptides require subcutaneous injection into fatty tissue. Never inject directly into a blood vessel or deep muscle tissue unless clinically detailed.
1. Site Selection
Common locations include the abdomen (2 inches from navel), outer upper arms, or thighs.
2. Sanitization
Thoroughly clean the selected site, stopper and vial top using 70% isopropyl alcohol prep swabs.
3. Angle & Push
Pinch the skin and insert the needle at a 45 to 90-degree angle. Depress plunger smoothly.
4. Site Rotation
Rotate injection sites continuously to avoid lipodystrophy or tissue scarring.
Frequently Asked Questions
What is the typical Livagen dosage?expand_more
Research dosing is 100–500 mcg subcutaneously per day across 10–20 day cycles, repeated 2–4 times per year. Oral capsule formulations in Russian bioregulator practice use 1–10 mg/day across 20–30 day cycles. There is no Western clinical reference standard.
How is Livagen administered?expand_more
Livagen is administered subcutaneously, intramuscularly, or orally. Subcutaneous injection achieves higher systemic exposure; oral capsules at higher milligram doses are used in outpatient Russian bioregulator practice despite low expected tetrapeptide bioavailability.
Can Livagen be stacked?expand_more
Livagen is commonly combined with other Khavinson bioregulators (Vladonix for thymus, Vilon for immune system, Epitalon for pineal) in Russian gerontology protocols targeting multiple organ systems. Combination with cardiovascular or musculoskeletal bioregulators is also described.
What are the side effects of Livagen?expand_more
Reported side effects are mild and infrequent: occasional injection-site discomfort, rare mild gastrointestinal upset with oral use, and rare hypersensitivity. Theoretical immune-modulation effects warrant caution in active autoimmune disease but have not produced clinical autoimmunity in observational use.
Is Livagen FDA approved?expand_more
No. Livagen is registered in Russia under peptide-bioregulator and dietary-supplement legislation but is not approved by the FDA, EMA, or MHRA. In the United States and EU it is sold only as a research chemical and is not licensed for therapeutic use.
Academic References & Study Citations
Khavinson VK. Peptides and ageing. Neuroendocrinol Lett. 2002;23 Suppl 3:11-144. View Scientific Paper →
Khavinson VK, Malinin VV. Gerontological aspects of genome peptide regulation. Karger Publishers, Basel; 2005. View Scientific Paper →
Lezhava T, Yurov Y, Vorsanova S, et al. Epigenetic regulation of chromatin condensation in human lymphocytes by Livagen peptide. Adv Gerontol. 2014;27(2):283-288. View Scientific Paper →
Lin'kova NS, Polyakova VO, Trofimov AV, Sevostyanova NN, Kvetnoy IM. Peptidergic regulation of thymopoiesis and immune function in aging. Adv Gerontol. 2011;24(1):38-53. View Scientific Paper →
Anisimov VN, Khavinson VK. Peptide bioregulation of aging: results and prospects. Biogerontology. 2010;11(2):139-49. View Scientific Paper →
Khavinson VK, Solovyev AY, Tarnovskaya SI, Lin'kova NS. Mechanism of biological activity of short peptides: cell penetration and epigenetic regulation. Bull Exp Biol Med. 2013;154(3):403-410. View Scientific Paper →
Khavinson VK, Popovich IG, Linkova NS, Mironova ES, Ilina AR. Peptide regulation of gene expression: a systematic review. Molecules. 2021;26(22):7053. View Scientific Paper →
Khavinson VK, Kvetnoy IM, Popovich IG, Anisimov VN. Mechanisms of biological activity of short peptides: cell-tissue specificity. Bull Exp Biol Med. 2020;168(3):378-381. View Scientific Paper →